Shirin Dalai
Family · Virginia Beach, VANPI 1346583846
Payments from drug & device makers
Across 467 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$672
- GSK$668
- Boehringer Ingelheim$533
- Corcept Therapeutics$506
- Pfizer$495
- plus $4K from 36 others
What the payments were for
- Food & beverage$8,70399%
- Education$1201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 88 | $1,540 |
| Novo Nordisk | 36 | $672 |
| GSK | 37 | $668 |
| Boehringer Ingelheim | 30 | $533 |
| Corcept Therapeutics | 24 | $506 |
| Pfizer | 28 | $495 |
| Lilly USA, LLC | 28 | $479 |
| Amgen | 24 | $412 |
| Astellas Pharma US Inc | 15 | $402 |
| Dexcom, Inc. | 12 | $331 |
| AbbVie | 17 | $315 |
| Exact Sciences | 14 | $308 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $288 |
| Novartis | 13 | $236 |
| Johnson & Johnson | 11 | $212 |
| Mannkind Corporation | 13 | $188 |
| Shield Therapeutics Inc | 3 | $174 |
| Almatica Pharma LLC | 7 | $136 |
| Otsuka America Pharmaceutical, Inc. | 7 | $134 |
| Medtronic | 4 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $78 |
| Merck | 3 | $59 |
| Esperion Therapeutics, Inc. | 3 | $53 |
| Abbott | 2 | $52 |
| Paratek Pharmaceuticals, Inc. | 3 | $50 |
| Verona Pharma, Inc. | 2 | $46 |
| Optinose US, Inc. | 2 | $43 |
| Lundbeck LLC | 2 | $37 |
| Eisai Inc. | 1 | $29 |
| Biogen | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Endo USA, Inc. | 1 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $22 |
| Recordati_rare_diseases_inc. | 1 | $22 |
| Nevro Corp. | 1 | $22 |
| Phadia US Inc. | 1 | $21 |
| Nestle Healthcare Nutrition Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Scynexis, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Nabriva Therapeutics, PLC | 1 | $13 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$112
- Saxenda$106
How this compares
$8,823 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 63 | $76,127 |
| FarxigaDapagliflozin Propanediol | 29 | $48,514 |
| Nurtec OdtRimegepant Sulfate | 13 | $38,842 |
| MounjaroTirzepatide | 27 | $35,402 |
| EliquisApixaban | 16 | $18,549 |
| JanuviaSitagliptin Phosphate | 21 | $18,548 |
| JardianceEmpagliflozin | 18 | $16,147 |
| XareltoRivaroxaban | 11 | $14,541 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $11,702 |
| LinzessLinaclotide | 12 | $8,711 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $3,947 |
| Levetiracetam | 21 | $2,101 |
| Omeprazole | 121 | $1,746 |
| Lubiprostone | 13 | $1,741 |
| Lidocaine | 18 | $1,556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $672 | $76,12763 claims |
| PfizerNurtec Odt, Eliquis | $495 | $57,39129 claims |
| AstraZenecaFarxiga | $1,540 | $48,51429 claims |
| Lilly USA, LLCMounjaro, Humulin 70-30 | $479 | $35,99840 claims |
| MerckJanuvia | $59 | $18,54821 claims |
| Boehringer IngelheimJardiance | $533 | $16,14718 claims |
| Johnson & JohnsonXarelto | $212 | $14,54111 claims |
| GSKTrelegy Ellipta | $668 | $11,70211 claims |
| AbbVieLinzess | $315 | $8,71112 claims |
| Almatica Pharma LLCSertraline Hcl | $136 | $78933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.
Other family in Virginia Beach
- Andrea CottonVirginia Beach$696K
- Rachel KingVirginia Beach$51K
- Laura JacksonVirginia Beach$22K
- Kim PhamVirginia Beach$13K
- Joseph BowmanVirginia Beach$11K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.